Primary Care Clinics in Florence, AZ Accepting Medicare
11 Primary Care Clinics found. Showing 1 - 11
 Horizon Health And Wellness, Inc. Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Medicare Enrolled Practice Location: 495 N Pinal Pkwy Ste 106, Florence, AZ 85132 Phone: 480-983-0065 |
Burke Medical Inc. Clinic/Center - Primary Care Medicare: Medicare Enrolled Practice Location: 3347 N Spyglass Dr., Florence, AZ 85132 Phone: -- |
U Medical Pllc Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 4545 N Hunt Hwy, Florence, AZ 85132 Phone: 520-868-3333 |
Fastmed Urgent Care Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 495 N Pinal Pkwy, Suite #106, Florence, AZ 85132 Phone: 520-868-0573 Fax: 520-868-0533 |
Lawrence W Bence Md Pc Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 150 S Main St, Florence, AZ 85132 Phone: 520-868-5811 Fax: 520-868-1223 |
Main Street Family Practice, P.c. Family Medicine Medicare: Medicare Enrolled Practice Location: 660 South Main Street, Florence, AZ 85232 Phone: 949-713-3998 |
Horizon Health And Wellness, Inc. Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 495 N Pinal Pkwy Ste 106, Florence, AZ 85132 Phone: 480-983-0065 |
Horizon Health And Wellness, Inc. Clinic/Center - Community Health Medicare: Not Enrolled in Medicare Practice Location: 495 N Pinal Pkwy Ste 106, Florence, AZ 85132 Phone: 480-983-0065 |
Ice Health Service Corps Clinic/Center - Public Health, Federal Medicare: Not Enrolled in Medicare Practice Location: 3250 N Pinal Pkwy, Florence, AZ 85132 Phone: 520-868-2049 Fax: 520-868-1547 |
Sun Life Family Health Center-florence Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Medicare Enrolled Practice Location: 174 W Highway 287, Florence, AZ 85132 Phone: 520-868-5811 Fax: 520-868-1223 |
Arizona Heart Institute Florence Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 200 South Main Street, Florence, AZ 85232 Phone: 520-868-8090 Fax: 602-240-6177 |
News Archive
Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
adaptiQ™ system for ready-to-use pharmaceutical vials launched by SCHOTT
SCHOTT introduced its adaptiQ™ system for ready-to-use pharmaceutical vials, which allows for more flexible manufacturing concepts and more efficient filling. Designed in close collaboration with filling line manufacturers to meet the pharmaceutical industry's process requirements, SCHOTT adaptiQ consists of a patented nest that securely holds as many as 100 clean and sterile vials in an industry standard tub.
Study looks at link between delivery time and outcomes for infants with birth defects
Weekday delivery is no better than night or weekend delivery for infants with birth defects, according to a new study presented today at The Pregnancy Meeting, the Society for Maternal-Fetal Medicine's annual conference. The finding is good news for all parties - moms, babies and healthcare teams - and suggests that this high-risk population of women should deliver when their bodies are ready to deliver, regardless of the day or time.
Insurer mounts offensive and defensive strategies on health law
Reporting for Kaiser Health News, Arlene Weintraub writes: "In the increasingly tense wrangling between the insurance industry and state regulators over the definition of what spending can qualify as medical care under the new health law, one of the loudest lobbying voices is a relatively small player: Cigna Corp" (Weintraub, 8/16).
Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease
Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.
› Verified 2 days ago